Omalizumab causes a reduction in the receptors present on dendritic cells (FcεRI), by blocking free IgE, whose role is fundamental in allergic asthma, thus restoring the ability to produce IFN-α [14,28,54,55]. Here, IFNA1 is linked to allergic asthma.